UOC
ATRS

UBS O'Connor’s Antares Pharma, Inc. ATRS Stock Holding History

UBS O'Connor’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200,000
Closed -$340K – 564
2015
Q3 		$340K Sell
200,000
-400,000
-67% -$784K 0.01% 431
2015
Q2 		$1.25M Buy
+600,000
New +$1.45M 0.02% 367
2014
Q3 		– Sell
-150,000
Closed -$400K – 560
2014
Q2 		$400K Sell
150,000
-70,000
-32% -$211K ﹤0.01% 370
2014
Q1 		$770K Sell
220,000
-30,000
-12% -$133K 0.01% 337
2013
Q4 		$1.12M Sell
250,000
-16,000
-6% -$65.2K 0.02% 294
2013
Q3 		$1.08M Sell
266,000
-209,000
-44% -$913K 0.02% 290
2013
Q2 		$1.98M Buy
+475,000
New +$1.83M 0.04% 329

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS O'Connor's ATRS Position: Q4 2015 in Review

UBS O'Connor sold out of Antares Pharma, Inc. (ATRS) in Q4 2015, closing a stake of 200,000 shares — an estimated $340K sold.

UBS O'Connor first reported a position in ATRS in Q2 2013 and held it in 7 quarters. The position peaked at $1.98M in Q2 2013. 88 funds tracked by Wall St. Rank hold ATRS as of Q4 2015.

  • UBS O'Connor reported no remaining Antares Pharma, Inc. position as of Q4 2015 after selling out during the quarter.
  • UBS O'Connor sold 200,000 Antares Pharma, Inc. shares in Q4 2015, an estimated $340K.
  • UBS O'Connor first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 7 quarters.
  • UBS O'Connor's Antares Pharma, Inc. position peaked at $1.98M in Q2 2013.
  • 88 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2015.

Based on UBS O'Connor's 13F filing for Q4 2015, filed 10 Feb 2016.